Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

CVS Health to purchase Aetna for $69 billion

CVS Health’s proposed purchase of Aetna will change the way many major U.S. corporations buy health coverage for employees, according to benefit consultants.

Read More »

The Medicines Co. Deals Infectious Disease Biz

The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. The deal is expected to close in the first quarter of 2018.

Read More »

Loxo Oncology, Bayer Strike Cancer Deal

Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.

Read More »

Zymeworks, Janssen Biotech Ink R&D Deal

Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.

Read More »

Boehringer, MiNA Therapeutics Forge NASH Deal

Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.

Read More »

CVS reportedly makes bid for Aetna

U.S. pharmacy operator CVS Health Corp. made an offer to acquire No. 3 U.S. health insurer Aetna Inc. for more than $200 per share, or over $66 billion, sources said.

Read More »

AbbVie bets on Alzheimer’s immunotherapy with big biotech deal

U.S. drugmaker AbbVie is betting on the potential of the body’s immune system to fight Alzheimer’s via a drug development deal worth more than $200 million with unlisted biotech company Alector.

Read More »

Visterra Inks $1B Deal With Vir Biotechnology

Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.

Read More »

Provention Bio and Johnson & Johnson Ink Deal

Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.

Read More »

AstraZeneca, Takeda strike Parkinson’s drug deal

AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom